C Number:

Study Gender:

PWG Approval Date

PA41: Clinical Chemistry Summary Test Compound: 2-ethylhexyl-2,3,4,5-tetrabromobenzoate CAS Number: 183658-27-7 Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

C13063-01 Male See web page for date of PWG Approval

PA41: Clinical Chemistry Summary Test Compound: 2-ethylhexyl-2,3,4,5-tetrabromobenzoate CAS Number: 183658-27-7

Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

	Treatment Groups (mg/kg)					
	Phase Day	0	0.05	0.55	5.5	55
Urea Nitrogen (mg/dL) Percent of Control	SD 5	12.4 ± 0.7 (5)	13.7 ± 0.4 (6) 110.2	13.0 ± 0.7 (5) 104.8	13.6 ± 1.5 (5) 109.7	13.8 ± 0.6 (5) 111.3
Creatinine (mg/dL) Percent of Control	SD 5	0.36 ± 0.02 (5)	0.37 ± 0.02 (6) 101.85	0.37 ± 0.02 (6) 101.85	0.34 ± 0.02 (5) 94.44	0.35 ± 0.02 (6) 97.22
Glucose (mg/dL) Percent of Control	SD 5	242.5 ± 9.4 (4)	263.5 ± 14.9 (6) 108.7	263.4 ± 18.9 (5) 108.6	244.6 ± 13.3 (5) 100.9	232.6 ± 9.2 (5) 95.9
Sodium (mmol/L) Percent of Control	SD 5	148.6 ± 0.2 (5)*	148.0 ± 0.4 (6) 99.6	147.8 ± 0.3 (6) 99.5	147.5 ± 0.4 (6) 99.3	147.8 ± 0.5 (6) 99.5
Potassium (mmol/L) Percent of Control	SD 5	7.8 ± 0.6 (5)	7.4 ± 0.2 (6) 94.0	7.5 ± 0.2 (6) 95.5	7.4 ± 0.3 (6) 94.2	7.0 ± 0.2 (6) 88.9
Chloride (mmol/L) Percent of Control	SD 5	101.0 ± 0.7 (5)*	101.0 ± 0.4 (6) 100.0	100.8 ± 0.5 (6) 99.8	100.3 ± 0.5 (6) 99.3	102.0 ± 0.6 (6) 101.0
Total Protein (g/dL) Percent of Control	SD 5	6.08 ± 0.21 (5)	5.67 ± 0.10 (6) 93.20	6.08 ± 0.18 (5) 100.00	5.96 ± 0.24 (5) 98.03	5.66 ± 0.09 (5) 93.09
Globulin (g/dL) Percent of Control	SD 5	1.62 ± 0.15 (5)	1.47 ± 0.07 (6) 90.53	1.62 ± 0.12 (5) 100.00	1.66 ± 0.16 (5) 102.47	1.42 ± 0.05 (5) 87.65
A/G Ratio Percent of Control	SD 5	2.83 ± 0.20 (5)	2.89 ± 0.11 (6) 102.23	2.81 ± 0.20 (5) 99.52	2.67 ± 0.21 (5) 94.59	3.00 ± 0.08 (5) 106.06
Albumin (g/dL) Percent of Control	SD 5	4.46 ± 0.07 (5)	4.20 ± 0.04 (6) * 94.17	4.40 ± 0.08 (6) 98.65	4.30 ± 0.08 (5) 96.41	4.28 ± 0.06 (6) 96.04
Cholesterol (mg/dL) Percent of Control	SD 5	150.8 ± 14.8 (4)	130.7 ± 2.4 (6) 86.7	141.3 ± 10.6 (6) 93.8	146.0 ± 12.3 (5) 96.8	132.8 ± 3.1 (6) 88.1

PA41: Clinical Chemistry Summary Test Compound: 2-ethylhexyl-2,3,4,5-tetrabromobenzoate CAS Number: 183658-27-7

Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

	Treatment Groups (mg/kg)					
	Phase Day	0	0.05	0.55	5.5	55
Triglyceride (mg/dL) Percent of Control	SD 5	78.4 ± 10.9 (5)	78.7 ± 11.4 (6) 100.3	79.6 ± 13.7 (5) 101.5	87.6 ± 17.2 (5) 111.7	83.8 ± 6.9 (6) 106.9
Alanine Aminotransferase (IU/L) Percent of Control	SD 5	56.4 ± 3.3 (5)	58.0 ± 2.1 (6) 102.8	63.3 ± 5.1 (6) 112.3	58.8 ± 3.5 (5) 104.3	55.3 ± 1.4 (6) 98.1
Creatine Kinase (IU/L) Percent of Control	SD 5	194.2 ± 14.7 (5)	185.2 ± 5.6 (6) 95.3	233.4 ± 33.5 (5) 120.2	224.5 ± 25.9 (6) 115.6	185.0 ± 10.9 (6) 95.3
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	5.8 ± 1.1 (5)	4.8 ± 1.1 (6) 83.9	7.3 ± 2.8 (5) 126.7	6.5 ± 1.0 (6) 112.3	8.0 ± 2.0 (5) 139.2
Bile salt/acids (umol/L) Percent of Control	SD 5	52.8 ± 10.4 (4) **	84.0 ± 9.1 (6) 159.2	70.4 ± 4.7 (5) 133.5	44.8 ± 7.5 (6) 85.0	37.2 ± 4.9 (5) 70.5

PA41: Clinical Chemistry Summary Test Compound: 2-ethylhexyl-2,3,4,5-tetrabromobenzoate CAS Number: 183658-27-7

Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

		Treatment Groups	
	Phase Day	550	
Urea Nitrogen (mg/dL) Percent of Control	SD 5	12.2 ± 0.7 (5) 98.4	
Creatinine (mg/dL) Percent of Control	SD 5	0.40 ± 0.00 (5) 111.11	
Glucose (mg/dL) Percent of Control	SD 5	244.7 ± 17.3 (3) 100.9	
Sodium (mmol/L) Percent of Control	SD 5	146.8 ± 0.5 (6)* 98.8	
Potassium (mmol/L) Percent of Control	SD 5	6.9 ± 0.4 (6) 88.2	
Chloride (mmol/L) Percent of Control	SD 5	103.0 ± 0.5 (6) 102.0	
Total Protein (g/dL) Percent of Control	SD 5	5.90 ± 0.03 (5) 97.04	
Globulin (g/dL) Percent of Control	SD 5	1.58 ± 0.05 (5) 97.53	
A/G Ratio Percent of Control	SD 5	2.75 ± 0.11 (5) 97.26	
Albumin (g/dL) Percent of Control	SD 5	4.32 ± 0.04 (5) 96.86	
Cholesterol (mg/dL) Percent of Control	SD 5	135.8 ± 5.5 (5) 90.1	

PA41: Clinical Chemistry Summary Test Compound: 2-ethylhexyl-2,3,4,5-tetrabromobenzoate CAS Number: 183658-27-7

Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

		Treatment Groups
	Phase Day	550
Triglyceride (mg/dL) Percent of Control	SD 5	87.0 ± 9.1 (5) 111.0
Alanine Aminotransferase (IU/L) Percent of Control	SD 5	53.4 ± 1.7 (5) 94.7
Creatine Kinase (IU/L) Percent of Control	SD 5	192.6 ± 16.9 (5) 99.2
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	11.7 ± 4.7 (3) 202.5
Bile salt/acids (umol/L) Percent of Control	SD 5	31.5 ± 5.9 (4) 59.7

Date Report Requested: 04/08/2019 Time Report Requested: 10:58:22 Lab: Battelle

LEGEND

Values given as mean ± SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD - Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

One value each for Bile salts/acids, Cholesterol and glucose in the 0 mg/kg group were excluded. One value each for A/G Ratio, Bile salts/acids, Creatine Kinase, Globulin, Glucose, Sorbitol Dehydrogenase, Total Protein, Triglycerides, and Urea Nitrogen in the 0.55 mg/kg group were excluded. One value each for Albumin, Alanine Aminotransferase, Cholestrol, Creatinine, Globulin, Glucose, Total Protein, and Urea Nitrogen in the 5.50 group were excluded. One value for Bile salts/acids and two values each for Glucose and Sorbitol Dehydrogenase in the 550 mg/kg group were excluded.

** END OF REPORT **